# Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer

> **NCT00856830** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 30 (actual)

## Conditions studied

- Small Cell Lung Cancer
- Extensive Stage Lung Cancer
- Chemonaive

## Interventions

- **DRUG:** Novel Drug Combination

## Key facts

- **NCT ID:** NCT00856830
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2015-05
- **Final completion:** 2016-05
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00856830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00856830, "Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00856830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*